Printer Friendly

Plasma Rich in Growth Factors Induces Cell Proliferation, Migration, Differentiation, and Cell Survival of Adipose- Derived Stem Cells.

1. Introduction

Adipose-derived stem cell (ASC) transplantation has already demonstrated effectiveness and continues to be an important avenue of research and development due to their extraordinary therapeutic aptitude. ASC transplantation has shown remarkable restorative ability reflected in the significant recovery of function in patients with a range of diseases such as Parkinson's, Alzheimer's, spinal cord injury, heart disease, and rheumatoid arthritis [1]. Nevertheless, new approaches for ASC isolation and amplification have been developed [2-4], to generate sufficient amount of stem cells to optimize clinical applications [5]. However, the paucity of information regarding ASC survival after transplantation lends itself to further investigation of ASC quantity and quality before transplantation. For instance, ASC activation with defined stimuli prior transplantation may enhance ASC repair capabilities and improve success rates for regenerative treatments. Recent studies have focused on increasing the yield, efficiency, and therapeutic capability of ASC by treating them with growth factors like PDGF or bFGF [6-8] or as a xenofree alternative for mesenchymal stem cell expansion [5, 9]. A major source of endogenous growth factors is the plasma rich in growth factors (PRGF) from platelet-rich plasma [10]. PRGF has been extensively used in many species to reduce healing time and to improve tissue regeneration [7, 11]. PRGF beneficial effects are modulated by the degranulation of alpha granules in platelets [12, 13] which contain several important growth factors that stimulate cell growth, proliferation, and differentiation [14, 15]. PRGF stimulates undifferentiated stem cells to proliferate and differentiate and has been used for tissue regeneration [8, 16-18] purposes. Undifferentiated stem cells migrate to the concentration of platelet-releasing growth factors triggering proliferation of the cells at the site [19]. Moreover, platelet-derived growth factors enhance sternness of ASC [20] being proposed as a gold standard fetal bovine serum replacing method for human cell propagation for clinical applications [5, 21, 22]. Additionally, PRGF has also shown synergistic properties on mesenchymal stem-induced differentiation which accelerate bone [23] or cartilage repair [24].

Minimizing aging of ASC cultures represents a significant challenge for tissue engineering especially for autologous cell-based approaches in geriatric patients [25]. New approaches have been considered to avoid ASC senescence for prolonged ex vivo expansion or induced differentiation avoiding, for instance, hypertrophic phenotypes on chondrocytes-induced differentiation process [26], by forcing the expression of hTERT, and telomerase activity induction, to extend the lifespan of the mesenchymal cells on culture. Previous reported data shows that hTERT-transduced mesenchymal stem cells have prolonged replicative capacity in vitro and keep the adipo-, chondro-, and osteogenic differentiation potential in vitro and osteogenic potential in vivo [27, 28]. Importantly, although there was no evidence for tumor formation or cell transformation, nongenetic manipulations will be more suitable for further potential clinical applications.

The serine/threonine kinase AKT represents an initial signaling node within all cells of higher eukaryotes contributing significantly to the regulation of survival, growth, proliferation, angiogenesis, and metabolism of many cell types [29]. AKT activation by PRGF enhances survival and regenerative function in ASC [30]. Furthermore, conditioning of ASC by inducing AKT activity increases cell survival and proangiogenic capacities [31]. The induction of cell survival signals, such as AKT, would also confer a resistance to hostile environments such as those associated with an inflammatory response, which induce cell death by oxidative stress [32].

2. Material and Methods

2.1. ASC Isolation and Culture. Adipose tissue was collected from dogs and humans, both of which were suffering from osteoarthritis, and was performed in an operating room by veterinarians and physicians, respectively. A 10 g biopsy of subcutaneous fat from dog patients [8] or from the suprapatellar fat pad from human patients [33] was collected, n = 4 (dogs) and n = 4 (humans). All procedures were performed under sterile conditions, and the adipose tissue was placed into sterile conical tubes containing sterile saline. The experimental procedures for dogs did not require evaluation by the animal Ethics Committee because the procedure only included a cession of part of the amplified ASCs needed for cell transplantation, and for this purpose, the canine owners voluntarily signed an informed consent for the use of surplus adipose tissue utilized for the derivation of ASCs and further research purposes. The human samples were anonymized, and this experimental procedure has been evaluated and accepted by the Regional Ethics Committee for Clinical Research with Medicines and Health Products following the Code of Practice 2014/01. As exclusion criteria, no samples were collected from patients with a history of cancer or infectious diseases at the time of the surgery (viral or bacterial). All human patients voluntarily signed an informed consent document for the use of surplus adipose tissue and donation of peripheral blood (20 ml) collected sodium citrate containing tubes for PRGF isolation prepared following the standardized method described in Anitua et al. [14], pooled to minimize differences between individuals and stored at -20[degrees]C.

Adipose tissue was transferred from the surgery room in an enclosed package at 4[degrees]C in sterile solution and arrived at the laboratory within 24 h after extraction. Each sample was washed multiple times in PBS plus antibiotics to clean the tissue and remove residual blood. Adipose tissue was then placed into sterile Petri dishes (10 g adipose tissue per 100 mm Petri dish), in a solution containing PBS, 100 units/ ml penicillin and 100 [micro]g/ml streptomycin (Gibco 15140), collagenase type I-A (0.07%, Sigma-Aldrich C9891 CA, USA), and dispase I (0.2 mM, Sigma-Aldrich). The adipose tissue was manually cut into small pieces using sterile surgical scissors in a laminar flow hood and transferred to a cell flask for overnight digestion in a shaker at 37[degrees]C, 20% [O.sub.2], and 5% C[O.sub.2]. On the following day, the digested adipose tissue was collected and washed multiple times with PBS plus antibiotics by serial centrifugation. The cell pellet was then resuspended in growth medium (DMEM containing 2 mM L-glutamine, 30% L-glucose, 100 units/ml penicillin, and 100 [micro]g/ml streptomycin), plus 10% fetal bovine serum (FBS) for canine samples or 10% human serum (HS) for human samples. On the following day, the medium was removed and replaced with fresh medium and attached cells were allowed to grow until nearly confluent and then subjected to cell proliferation, survival studies, and cell differentiation assays.

2.2. Cell Proliferation Assay. At passages 3-4, canine and human ASCs, [10.sup.4] cells were seeded in 24-well plates in the presence of 10% of FBS or HS, respectively, for 24 hours. Then, the medium was replaced for 0, 1, 2.5, 5, or 10% of FBS or HS or PRGF-containing medium and cells were maintained on culture for 24 hours incubation. For cell quantification, each well was trypsinized and counted in a Neubauer[R] chamber. Three independent experiments were performed in triplicates. Data was expressed as mean [+ or -] SD.

2.3. Cell Migration and Invasion Analysis by In Vitro Scratch Assay. Cell migration for wound healing of the induced in vitro scratch was performed in the IncuCyte[R] S3 live-cell analysis [34, 35]. 15 x [10.sup.5] ASCs were seeded in 96-well plates for a monolayer cell culture in the presence of 10% of HS. 24 hours after seeding, the scratch was performed at the time in all wells by using the WoundMaker tool. Then, the medium was replaced by 0% HS or PRGF, 2.5%, or 10% of HS or PRGF in triplicates. Cell growth and migration were monitored under phase-contrast microscopy connected to a time-lapse recording system at the scratched area, every hour during 16 h. A picture from four different fields at each experimental condition was recorded for time-lapse reconstruction and to quantify the cell density of repopulated scratched area. Image analysis was automatically performed by the associated software by following the reported mathematical analysis in [35]. The results are shown as the mean [+ or -] SD of the % of relative wound density at every experimental condition.

2.4. Senescence-Associated Beta-Galactosidase (SApGal) Activity. Cells were seeded at 2000 cells/[cm.sup.2] in six-well plates in the presence of 10% of HS. 24 hours after seeding, the medium was replaced for 2.5% PRGF, 2.5% HS, 10% HS, or 0% of PRGF or HS. 48 hours after incubation, cells were fixed in 4% paraformaldehyde for 10 minutes and assayed for SA[beta]-Gal activity as described by Debacq-Chainiaux et al. [36]. SA[beta]Gal-positive cells were counted with a minimum of 200 cells overall for each condition. Three independent experiments were performed. Data was expressed as the mean [+ or -] SD of the percentage ratio of [beta]Gal-positive cells within the total assayed cell culture.

2.5. Transmission Electron Microscopy and Autophagosome Quantification. Cells were seeded at 2000 cells/[cm.sup.2] in LabTek chamber slides (Nalge Nunc International, Naperville, IL) in the presence of 10% of HS. 24 hours after seeding, the medium was replaced for 2.5% PRGF, 2.5% HS, 10% HS, or 0% of PRGF or HS. 48 hours after incubation, cells were fixed in 3% glutaraldehyde for 1 hour at 37[degrees]C. Cells were post fixed in 2% Os[O.sub.4] for 1 hour at room temperature and stained in 1% uranyl acetate in the dark for 2 h at 4[degrees]C. Finally, cells were rinsed in distilled water, dehydrated in ethanol, and infiltrated overnight in Durcupan resin (Fluka, Sigma-Aldrich, St. Louis, USA). Following polymerization, embedded cultures were detached from the chamber slide and glued to araldite blocks. Serial semithin sections (1.5 [micro]m) were cut with an Ultra cut UC-6 (Leica, Heidelberg, Germany) and mounted onto slides and stained with 1% toluidine blue. Selected semithin sections were glued with Super Glue-3, Loctite (Henkel, Dusseldorf, Germany) to araldite blocks and detached from the glass slide by repeated freezing (in liquid nitrogen) and thawing. Ultrathin sections (0.06-0.08 [micro]m) were prepared with the Ultra cut and stained with lead citrate. Finally, photomicrographs were obtained under a transmission electron microscope FEI Tecnai G2 Spirit (FEI Europe, Eindhoven, Netherlands) using a digital camera Morada (Olympus Soft Image Solutions GmbH, Munster, Germany). Autophagosomes were morphologically identified (*) and quantified from at least 10 different pictures, at equal magnification, for each experimental condition and normalized to the total cell area by using the ImageJ software in pixels ([px.sup.2]). Three independent experiments were performed, and data was expressed as mean [+ or -] SD of autophagosomes/total cell area ([px.sup.2]).

2.6. ASC-Directed Differentiation. Confluent canine and human ASCs at passage 4 were subjected to directed differentiation towards adipocytes, osteocytes, or chondrocytes [37]. All three differentiation processes were performed in parallel with 2.5% thawed PRGF plus heparin (40 U) or heparin alone. All directed differentiation media were obtained from Lonza Group Ltd.

2.6.1. Adipogenesis. ASCs were seeded at a cell density of 10,000 cells/[cm.sup.2], and when ASCs were >90% confluent, the growth medium was changed to differentiation medium containing insulin, dexamethasone, IBMX (3-isobutylmethyl-xantine), and indomethacin (adipose-derived stem cell Basal Medium; Lonza Group Ltd.). The cells were then incubated for 10-12 days. Adipogenic differentiation was evaluated by Oil Red O staining of the lipid vacuoles in formalin-fixed cultures.

2.6.2. Osteogenesis. ASCs were seeded at a cell density of 10,000 cells/[cm.sup.2] in collagen I-coated plates (Sigma-Aldrich; 10 mM) in medium containing 0.1 [micro]M dexamethasone, 50 [micro]M Asc2P, and 10 mM [micro]-glycerophosphate (osteogenic basal medium; Lonza Group Ltd.) with 10% human serum. ASC cultures were maintained in this medium for 4 weeks (with medium changes every 3 days). For detection of extracellular calcium deposits, Alizarin Red staining was used in formalin-fixed cultures. Immunodetection, by immunofluorescence, was performed to detect actin filaments by phalloidin and osteocytes by Connexin 43.

2.6.3. Chondrogenesis. Differentiation of chondrocytes was performed using a micromass. Starting with a high concentration of ASC in a minimal volume (1 x [10.sup.5] cells/100 [micro]l) in the presence of TGF-[beta]1 and 3 (10ng/ml), Asc 2P (50 [micro]M), and insulin (6.25 [micro]g/ml) (Chondro BulletKit; Lonza Group Ltd.), these ASCs were cultured for four weeks in this medium, with medium changes every 3 days. Alcian blue was used to detect the presence of enrichment of sulfated proteoglycans in the extracellular matrix. Before staining, the micromass cultures were fixed in formalin, embedded in paraffin, and cut into 5 [micro]m sections.

2.7. Immunocytochemistry. ASC monolayer was fixed with 4% PFA at room temperature for 15 minutes, permeabilized with 0.1% Triton X-100, and subsequently blocked with 10% FBS. Micromass sections from chondrocyte-induced differentiation were previously dewaxed. Incubation with one of the following primary antibodies was performed overnight (1: 200) at 4[degrees]C: Connexin 43 (Abcam; UK); Sox9 (Chemicon, USA). After removing primary antibodies and washing thoroughly, one of the following secondary antibodies (1 : 400) was added and incubated for 1 h at room temperature; Oregon green 488 goat anti-mouse IgG or Alexa Fluor 647 mouse anti-rabbit (Thermo Fisher Scientific, USA). Phalloidin conjugated with FITC (1 : 1000; Invitrogen, USA) was incubated for 45 minutes before visualization. All cells were counter-stained by incubation with 4,6-diamidino-2-phenylindole dihydrochloride (DAPI) from Molecular Probes (Invitrogen, USA) for 3 min at room temperature followed by washing steps. Samples were mounted using FluorSave Reagent (Calbiochem, USA). Confocal Microscopy (Leica, Germany) was employed to visualize the signals; at least six different fields per condition and assay were analysed.

2.8. ASC Treatments and Survival Studies in the Presence of Hydrogen Peroxide. The [H.sub.2][O.sub.2] (Sigma-Aldrich, USA) and AKT inhibitors (Calbiochem, USA; AKT inhibitor VIII 124018; 10 [micro]M) were freshly prepared from 1M and 10 mM stock solutions, respectively. PRGF and [H.sub.2][O.sub.2] combined treatments were incubated at the same time. AKT inhibitor was preincubated for 30 minutes prior to secondary treatments.

The cell viability was determined by the CellTiter 96[R] AQueous Non-Radioactive Cell Proliferation Assay (Promega Co., Madison, WI, USA) following the manufacturer's instructions. Briefly, [10.sup.5] ASCs at passages 2-5 were seeded onto 96-well plates and allowed to grow for 24 h in growth medium. After removing the growth medium, the cells were treated with PRGF (0 or 2.5%, plus 40 U of heparin), 2.5% of HS, [H.sub.2][O.sub.2] (100 [micro]M), and/or AKT inhibitor (Calbiochem, USA; AKT Inhibitor VIII 124018; 10[micro]M) for 24h in the absence of serum. Every condition was assayed in quadruplicate in three different experiments. The viability of cells at each assayed condition was expressed as the percentage ratio of the mean [+ or -] SD.

2.9. Annexin VDetection by FACS Analysis. ASCs were trypsinized, and [10.sup.5] cells per condition were diluted into 100 [micro]l of PBS and incubated with 1: 50 dilution of annexin V-FITC-conjugated antibody (Invitrogen, USA) in the dark for 45 min at room temperature and then washed three times with PBS and resuspended in 0.3 ml of cold PBS for flow cytometry analysis (FC500, Beckman Cultek, USA). The mean [+ or -] SD of the annexin V-positive population (in percentage) of all tested samples were represented.

2.10. Western Blotting Analysis. ASCs were collected, and proteins were extracted by using Lysis Buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.02% Na[N.sub.3], 0.1 SDS, 1% NP40, 1 mM EDTA, 2 [micro]g/ml leupeptin, 2 [micro]g/ml aprotinine, 1 mM PMSF, and 1x Protease Inhibitor Cocktail (Roche Diagnostics, USA)). Equal amounts of protein extracts (20 [micro]g) were loaded onto a 10% SDS-polyacrylamide gel and resolved by standard SDS-PAGE. Proteins were electrophoretic transferred onto PVDF membranes. Membranes were blocked with 5% skim milk in PBST for 60 min and incubated overnight with one of the following specific primary antibodies (1:1000): PARP (Abcam, UK); P-AKT, AKT, or Cyclin D (Cell Signaling, USA). [beta]-Actin (1:5000) (Sigma-Aldrich, USA) was used as a loading control. Subsequently, membranes were incubated with rabbit anti-mouse or rabbit anti-goat horseradish peroxidase-conjugated secondary antibody (1 : 5000) (Sigma-Aldrich, USA). Blots were visualized by the ECL detection system (Amersham, UK).

2.11. Statistical Analysis. Statistical comparisons by pairs were assessed by Student's t-test. All P values were derived from a two-tailed statistical test using the SPSS 11.5 software. A value of P < 0.05 was considered statistically significant.

3. Results

3.1. PRGF Induces Proliferation and Migration of ASCs. Human ASCs in the presence of growing concentrations of HS or PRGF (1, 2.5, 5, or 10%), for 24 h, exhibited significant increased proliferation in comparison with absent of growth factors (0%; Figure 1(a), left graph; * P > 0.05). 10% of PRGF induced the highest proliferation rates and was significantly different to the HS proliferative activity (Figure 1(a), left graph; $ P > 0.05). Representative phase-contrast images of human ASCs in the presence of 10% HS or PRGF are shown in Figure 1(a) (right). Similarly, in a cell invasion scratch assay, 10% of PRGF induced the highest cell migration activity, significantly different in comparison with ASC in the presence of HS (Figure 1(b), left graph). Representative photograms from time-lapse analysis, 16 hours after PRGF or HS treatments, evidenced both the increase of cell density and the accelerated wound invasion induced by 10% PRGF (Figure 1(b), right panels). Canine ASCs showed comparable respond to human ASCs. 10% of canine PRGF induced higher proliferation rates in comparison with FBS containing canine ASC cultures (Supplementary Figure 1 available online at

3.2. PRGF Reduces Senescence and Autophagocytosis of In Vitro Expanded ASC. Ex vivo amplification of ASCs has shown to be limited to a certain number of passages constituting a limitation for generation of sufficient high cell quantities on clinical usage. Indeed, cellular alterations occurring during in vitro aging have been suggested to be similar to differences observed on ASCs from aged and young donors [38]. There is increasing evidence that cellular senescence is a cause of stem cell aging and malignancy [39]. Herein, we report that 2.5% of PRGF reduces senescence of human ASCs upon starvation, in the absence of growth factors, but not the equivalent concentration of HS, in comparison with the total absent of growth factors (Figure 2(a)). Similarly, the significant accumulation of autophagosomes, a hallmark of cell aging [40], induced by the lack of growth factors, was significantly prevented with 2.5% of PRGF and not with the same concentration of HS (Figure 2(b); graph). Transmission electron microscopy representative images show an extensive accumulation of autophagosome bodies (*) and vacuoles ($) in the complete absence of growth factors and in less extend, but also significant, in the ASCs in the presence of 2.5% of HS (Figure 2(b); upper panels). A dose response of PRGF on reducing senescence and autophagocytosis was assayed also for 5 and 10% of PRGF, and no significant differences were found in comparison with 2.5% PRGF (data not shown).

3.3. PRGF Accelerates ASC-Directed In Vitro Differentiation of Adipocytes, Osteocytes, and Chondrocytes. Human ASCs in the presence of PRGF differentiated more rapidly toward adipocytes, osteocytes, and chondrocytes (Figures 3(a), 3(b) and 3(c)). Human ASCs were induced to differentiate into the three mesodermal lineages, in the presence or absence of 2.5% PRGF in the defined differentiated mediums for each lineage. Directed adipogenesis revealed a more rapid accumulation of fat-containing cells in the presence of PRGF, as visualized and quantified by the Oil Red O staining (Figure 3(a)). Osteocyte differentiation in the presence of PRGF was even more robust and accelerated. PRGF treatment leads to increased expression of Cx43, a known marker of mature osteocytes, at four weeks of the differentiation process and a higher number of calcium containing osteocyte cell clusters as demonstrated by Alizarin Red staining quantification (Figure 3(b)). ASCs differentiated toward chondrocytes showed higher Sox9 expression in the presence of PRGF (Figure 3(c), right panels). In addition, cell number and density increased in the presence of PRGF, with an enrichment of collagen in the micromass cultures for chondrocyte induction as visualized and quantified by Alcian blue staining (Figure 3(c), left panels). Canine PRGF also improved the yield on the directed differentiation process into adipocytes, osteocytes, and chondrocytes as shown in the representative images of Supplementary Figure 2.

3.4. PRGF Exhibits Improved Tolerance to Hydrogen Peroxide Cytotoxicity in Human ASCs by AKT Induction. Acute bouts of oxidative stress stimulate cell proliferation in ASCs [41]; however, high doses, or extended exposure to low doses of reactive oxygen species, dramatically reduce ASC viability [42]. Treatment with 100 [micro]M [H.sub.2][O.sub.2] for 24 h was significantly toxic to human ASCs in the absence of growth factors (Figure 4(a)). Consistent with the perceived cytoprotective effect of PRGF, quantification of cell viability revealed that in the presence of 2.5% PRGF, but not 2.5% HS, PRGF significantly prevented the cell death that was significantly compromised by the addition of 100 [micro]M [H.sub.2][O.sub.2] (Figure 4(a)).

Pharmacological inhibition of AKT by the preincubation for 30 minutes with 10 [micro]M of the Inhibitor VIII 124018 (Calbiochem) blocked the protective effect of 2.5% of PRGF on ASCs exposed to a cytotoxic [H.sub.2][O.sub.2] dose (Figure 4(b)). Furthermore, the percentage of the population of apoptotic cells, quantified by the expression of annexin V, was determined in the presence or absence of PRGF and when treated with [H.sub.2][O.sub.2] alone or with AKT inhibitor. The results demonstrated that PRGF induced cell survival via activation of AKT since the inhibition of AKT leads to a significant population of annexin V-positive cells, including those in the presence of PRGF (Figure 4(c)).

ASCs require of trophic factors since in the absence of PRGF or HS, there was an increase of basal activation of apoptosis as evidenced by the cleavage of PARP, a protein associated with the induction of apoptosis signaling [43] (Figure 4(d)). Moreover, the presence of PRGF blocked the induced PARP cleavage when ASCs were treated with 100 [micro]M [H.sub.2][O.sub.2]. In the presence of PRGF, phosphorylated AKT (active form) and cyclin D (downstream effector of AKT) are expressed when PARP has not been cleaved.

4. Discussion

ASCs and PRGF have been shown as promising therapeutic alternatives for tissue repair in mesoderm-related tissues, like, for instance, in the repair of the damaged cartilage in osteoarthritis. ASCs are easily expanded in culture and are capable of differentiating by their multipotent nature in various mature cell lineages allowing to reproduce in vitro processes such as osteogenesis, chondrogenesis, or adipogenesis [44]. However, still there is much uncertain information about the ex vivo amplification, behaviour of the transplanted cells in terms of cell survival, tissue integration, or cell differentiation in a hostile microenvironment. Nowadays, PRGF offers an autologous source of known regenerative properties being able to synergistically improve the benefits of ASC treatments. PRGF favors ASC proliferation [7, 8] and is able to stimulate undifferentiated stem cell differentiation for tissue regeneration [17, 45]. Undifferentiated stem cells migrate to the concentration of PRGF growth factor gradients, and the growth factors trigger proliferation of these cells once they are at the site of administration [46]. The combinatory use of PRGF and ASCs has already shown improved benefits in a number of tissue repair process, including osteoarthritis or by accelerating ossification of fractures [47-49].

Cell transplantation efficiency is directly depending on cell survival, cell aging, and cell fate specification. Rejuvenation of aged progenitor cells has been largely reported by exposure to a young or regenerative environment by reducing the cell senescence [50]. Recent studies suggest that blood from young donors could reverse age-related diseases based on experiments of blood transference from young mice which could rejuvenate aged tissues in older animals [50-52]. After analyzing several circulating factors, Loffredo et al. [52] suggested that GDF11 could be responsible for these effects. Recently, Bueno et al. [53] have shown that GDF11 is at least ten times more concentrated in platelet lysate than in serum or plasma, indicating that GDF11 is stored in platelets contributing most probably to the differential effect of PGRF on cell proliferation, cell differentiation, or cell aging [54]. We have observed a significant dependency on the AKT signaling activation with survival responses in ASCs in the absence of growth factors and by oxidative damage. PRGF by inducing phosphorylation of AKT significantly improves cell survival of ASCs when are exposed to proapoptotic concentrations of hydrogen peroxide. The hydrogen peroxide is employed to reproduce the oxidative stress found at the injury and transplantation area. The inflammatory-related oxidative stress in fact compromises the cell function and survival of the entire joint, including the cartilage in the osteoarthritic patients [55]. In this context, PRGF treatment would prevent cell death associated to oxidative stress by inducing prosurvival signals in the joint by activation of AKT [56].

The efficiency of ASCs for osteoarthritis has been already probed with significant functional improvements. Dogs provide a suitable translational model for further clinical research on osteoarthritis, with close histopathological and functional features [57]. We recently showed in a randomized study performed in canine patients, with moderate to severe osteoarthritis, that intra-articular transplantation of ASC provided a significant joint functional improvement, reducing dog's pain and improving physical function up to six months [58, 59]. In fact, ASCs from canine samples were also tested in vitro, in response to PRGF, and we found a similar response to cell proliferation, survival, and differentiation found in human ASCs (Supplementary Figure). Based on in vitro experimentation, significant improvements would be expected for activated ASCS by PRGF stimulation; however, further in vivo analysis is needed to disclose it. Thus, ASCs in culture pretreated with PRGF before transplantation may confer improved survival, proliferation, and antiapoptotic capabilities and render the cells a powerful source for cell therapy and tissue regeneration. Canine and human ASCs showed a comparable response to PRGF of cell proliferation, cell differentiation, and AKT induction. Thereby, dogs provide a suitable translational model for further clinical research on ASC-based treatments.

5. Conclusion

PRGF treatment is a potent stimulator of ASCs and can be used as an autologous preconditioning agent to enhance the therapeutic potential of ASC transplantation. 10.1155/2017/5946527

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors' Contributions

Richard J. Griffeth, Montserrat Garcia, Ramon Cugat, Victoria Moreno-Manzano, Maravillas Mellado-Lopez, and Jose Meseguer-Ripolles collected and/or assembled, analysed, and interpreted the data. Montserrat Garcia, Ramon Cugat, and Victoria Moreno-Manzano gave their financial support. Maravillas Mellado-Lopez and Richard J. Griffeth contributed equally to this work.


The authors specially acknowledge the Fundacion Garcia Cugat for its financial and various intellectual support. This work was also supported by the Ministerio de Economia y Competitividad (Grant no. CONSOLIDER-INGENIO 2010 CSD2008-00005) and the MINECO (Grant no. MAT201566666-C3-1-R).


[1] L. E. Kokai, K. Marra, and J. P. Rubin, "Adipose stem cells: biology and clinical applications for tissue repair and regeneration," Translational Research, vol. 163, no. 4, pp. 399-408, 2014.

[2] D. C. Colter, R. Class, C. M. DiGirolamo, and D. J. Prockop, "Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3213-3218, 2000.

[3] B. A. Bunnell, M. Flaat, C. Gagliardi, B. Patel, and C. Ripoll, "Adipose-derived stem cells: isolation, expansion and differentiation," Methods, vol. 45, no. 2, pp. 115-120, 2008.

[4] S. Riis, V. Zachar, S. Boucher, M. C. Vemuri, C. P. Pennisi, and T. Fink, "Critical steps in the isolation and expansion of adipose-derived stem cells for translational therapy," Expert Reviews in Molecular Medicine, vol. 17, article e11, 2015.

[5] G. Astori, E. Amati, F. Bambi et al., "Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future," Stem Cell Research & Therapy, vol. 7, no. 1, p. 93, 2016.

[6] K. Chieregato, S. Castegnaro, D. Madeo, G. Astori, M. Pegoraro, and F. Rodeghiero, "Epidermal growth factor, basic fibroblast growth factor and platelet-derived growth factor-bb can substitute for fetal bovine serum and compete with human platelet-rich plasma in the ex vivo expansion of mesenchymal stromal cells derived from adipose tissue," Cytotherapy, vol. 13, no. 8, pp. 933-943, 2011.

[7] R. J. Griffeth, D. Garcia-Parraga, M. Mellado-Lopez et al., "Platelet-rich plasma and adipose-derived mesenchymal stem cells for regenerative medicine-associated treatments in bottlenose dolphins (Tursiops truncatus)," PLoS One, vol. 9, no. 9, article e108439, 2014.

[8] F. J. Rodriguez-Jimenez, T. Valdes-Sanchez, J. M. Carrillo et al., "Platelet-rich plasma favors proliferation of canine adipose-derived mesenchymal stem cells in methacrylate-endcapped caprolactone porous scaffold niches," Journal of Functional Biomaterials, vol. 3, no. 3, pp. 556-568, 2012.

[9] S. Mohammadi, M. Nikbakht, A. Malek Mohammadi et al., "Human platelet lysate as a xeno free alternative of fetal bovine serum for the in vitro expansion of human mesenchymal stromal cells," International Journal of Hematology-Oncology and Stem Cell Research, vol. 10, no. 3, pp. 161-171, 2016.

[10] P. Borrione, A. D. Gianfrancesco, M. T. Pereira, and F. Pigozzi, "Platelet-rich plasma in muscle healing," American Journal of Physical Medicine & Rehabilitation, vol. 89, no. 10, pp. 854-861, 2010.

[11] C. J. Meheux, P. C. McCulloch, D. M. Lintner, K. E. Varner, and J. D. Harris, "Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review," Arthroscopy, vol. 32, no. 3, pp. 495-505, 2016.

[12] R. E. Marx, "Platelet-rich plasma: evidence to support its use," Journal of Oral and Maxillofacial Surgery, vol. 62, no. 4, pp. 489-496, 2004.

[13] B. L. Eppley, W. S. Pietrzak, and M. Blanton, "Platelet-rich plasma: a review of biology and applications in plastic surgery," Plastic and Reconstructive Surgery, vol. 118, no. 6, pp. 147e-159e, 2006.

[14] E. Anitua, C. Carda, and I. Andia, "A novel drilling procedure and subsequent bone autograft preparation: a technical note," The International Journal of Oral & Maxillofacial Implants, vol. 22, no. 1, pp. 138-145, 2007.

[15] P. Niemeyer, K. Fechner, S. Milz et al., "Comparison of mesenchymal stem cells from bone marrow and adipose tissue for bone regeneration in a critical size defect of the sheep tibia and the influence of platelet-rich plasma," Biomaterials, vol. 31, no. 13, pp. 3572-3579, 2010.

[16] M. Dominici, K. Le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement," Cytotherapy, vol. 8, no. 4, pp. 315-317, 2006.

[17] G. J. Hausman and R. L. Richardson, "Adipose tissue angiogenesis," Journal of Animal Science, vol. 82, no. 3, pp. 925-934, 2004.

[18] J. G. Neels, T. Thinnes, and D. J. Loskutoff, "Angiogenesis in an in vivo model of adipose tissue development," The FASEB Journal, vol. 18, no. 9, pp. 983-985, 2004.

[19] S. V. Kevy and M. S. Jacobson, "Comparison of methods for point of care preparation of autologous platelet gel," The Journal of Extra-Corporeal Technology, vol. 36, no. 1, pp. 28-35, 2004.

[20] M. Tobita, S. Tajima, and H. Mizuno, "Adipose tissue-derived mesenchymal stem cells and platelet-rich plasma: stem cell transplantation methods that enhance stemness," Stem Cell Research & Therapy, vol. 6, p. 215, 2015.

[21] R. X. Wu, Y. Yu, Y. Yin, X. Y. Zhang, L. N. Gao, and F. M. Chen, "Platelet lysate supports the in vitro expansion of human periodontal ligament stem cells for cytotherapeutic use," Journal of Tissue Engineering and Regenerative Medicine, vol. 11, no. 8, pp. 2261-2275, 2016.

[22] T. Burnouf, D. Strunk, M. B. Koh, and K. Schallmoser, "Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation?," Biomaterials, vol. 76, pp. 371-387, 2016.

[23] J. van den Dolder, R. Mooren, A. P. Vloon, P. J. Stoelinga, and J. A. Jansen, "Platelet-rich plasma: quantification of growth factor levels and the effect on growth and differentiation of rat bone marrow cells," Tissue Engineering, vol. 12, no. 11, pp. 3067-3073, 2006.

[24] R. J. do Amaral, A. Matsiko, M. R. Tomazette et al., "Platelet-rich plasma releasate differently stimulates cellular commitment toward the chondrogenic lineage according to concentration," Journal of Tissue Engineering, vol. 6, 2015.

[25] K. Mareschi, I. Ferrero, D. Rustichelli et al., "Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow," Journal of Cellular Biochemistry, vol. 97, no. 4, pp. 744-754, 2006.

[26] M. B. Mueller, M. Fischer, J. Zellner et al., "Hypertrophy in mesenchymal stem cell chondrogenesis: effect of TGF-[beta] isoforms and chondrogenic conditioning," Cells Tissues Organs, vol. 192, no. 3, pp. 158-166, 2010.

[27] J. L. Simonsen, C. Rosada, N. Serakinci et al., "Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells," Nature Biotechnology, vol. 20, no. 6, pp. 592-596, 2002.

[28] S. Shi, S. Gronthos, S. Chen et al., "Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression," Nature Biotechnology, vol. 20, no. 6, pp. 587-591, 2002.

[29] B. D. Manning and L. C. Cantley, "AKT/PKB signaling: navigating downstream," Cell, vol. 129, no. 7, pp. 1261-1274, 2007.

[30] Y. Peng, S. Huang, Y. Wu et al., "Platelet rich plasma clot releasate preconditioning induced PI3K/AKT/NFkB signaling enhances survival and regenerative function of rat bone marrow mesenchymal stem cells in hostile microenvironments," Stem Cells and Development, vol. 22, no. 24, pp. 3236-3251, 2013.

[31] A. M. Bader, K. Klose, K. Bieback et al., "Hypoxic preconditioning increases survival and pro-angiogenic capacity of human cord blood mesenchymal stromal cells in vitro," PLoS One, vol. 10, no. 9, article e0138477, 2015.

[32] J. L. Martindale and N. J. Holbrook, "Cellular response to oxidative stress: signaling for suicide and survival," Journal of Cellular Physiology, vol. 192, no. 1, pp. 1-15, 2002.

[33] I. Munoz-Criado, J. Meseguer-Ripolles, M. Mellado-Lopez et al., "Human suprapatellar fat pad-derived mesenchymal stem cells induce chondrogenesis and cartilage repair in a model of severe osteoarthritis," Stem Cells International, vol. 2017, Article ID 4758930, 12 pages, 2017.

[34] S. T. Johnston, J. V. Ross, B. J. Binder, D. L. Sean McElwain, P. Haridas, and M. J. Simpson, "Quantifying the effect of experimental design choices for in vitro scratch assays," Journal of Theoretical Biology, vol. 400, pp. 19-31, 2016.

[35] S. T. Johnston, E. T. Shah, L. K. Chopin, D. L. Sean McElwain, and M. J. Simpson, "Estimating cell diffusivity and cell proliferation rate by interpreting IncuCyte ZOOM[TM] assay data using the Fisher-Kolmogorov model," BMC Systems Biology, vol. 9, p. 38, 2015.

[36] F. Debacq-Chainiaux, J. D. Erusalimsky, J. Campisi, and O. Toussaint, "Protocols to detect senescence-associated beta-galactosidase (SA-[beta]gal) activity, abiomarkerof senescent cells in culture and in vivo," Nature Protocols, vol. 4, no. 12, pp. 1798-1806, 2009.

[37] S. P. Johnson, J. M. Catania, R. J. Harman, and E. D. Jensen, "Adipose-derived stem cell collection and characterization in bottlenose dolphins (Tursiops truncatus)," Stem Cells and Development, vol. 21, no. 16, pp. 2949-2957, 2012.

[38] W. Wagner, S. Bork, P. Horn et al., "Aging and replicative senescence have related effects on human stem and progenitor cells," PLoS One, vol. 4, no. 6, article e5846, 2009.

[39] J.-P. Coppe, C. K. Patil, F. Rodier et al., "Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor," PLoS Biology, vol. 6, no. 12, article e301, 2008.

[40] D. C. Rubinsztein, G. Marino, and G. Kroemer, "Autophagy and aging," Cell, vol. 146, no. 5, pp. 682-695, 2011.

[41] S. Kang, J. Han, S. Y. Song et al., "Lysophosphatidic acid increases the proliferation and migration of adipose-derived stem cells via the generation of reactive oxygen species," Molecular Medicine Reports, vol. 12, no. 4, pp. 5203-5210, 2015.

[42] S. Kang, S. M. Kim, and J. H. Sung, "Cellular and molecular stimulation of adipose-derived stem cells under hypoxia," Cell Biology International, vol. 38, no. 5, pp. 553-562, 2014.

[43] G. V. Chaitanya, A. J. Steven, and P. P. Babu, "PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration," Cell Communication and Signaling, vol. 8, p. 31, 2010.

[44] G. Lin, M. Garcia, H. Ning et al., "Defining stem and progenitor cells within adipose tissue," Stem Cells and Development, vol. 17, no. 6, pp. 1053-1063, 2008.

[45] E. M. Horwitz, K. Le Blanc, M. Dominici et al., "Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement," Cytotherapy, vol. 7, no. 5, pp. 393-395, 2005.

[46] V. Cervelli, M. G. Scioli, P. Gentile et al., "Platelet-rich plasma greatly potentiates insulin-induced adipogenic differentiation of human adipose-derived stem cells through a serine/threonine kinase Akt-dependent mechanism and promotes clinical fat graft maintenance," Stem Cells Translational Medicine, vol. 1, no. 3, pp. 206-220, 2012.

[47] S. Tajima, M. Tobita, H. Orbay, H. Hyakusoku, and H. Mizuno, "Direct and indirect effects of a combination of adipose-derived stem cells and platelet-rich plasma on bone regeneration," Tissue Engineering Part A, vol. 21, no. 5-6, pp. 895-905, 2015.

[48] K. Li, F. Li, J. Li et al., "Increased survival of human free fat grafts with varying densities of human adipose-derived stem cells and platelet-rich plasma," Journal of Tissue Engineering and Regenerative Medicine, vol. 11, no. 1, pp. 209-219, 2017.

[49] F. Hildner, C. Albrecht, C. Gabriel, H. Redl, and M. van Griensven, "State of the art and future perspectives of articular cartilage regeneration: a focus on adipose-derived stem cells and platelet-derived products," Journal of Tissue Engineering and Regenerative Medicine, vol. 5, no. 4, pp. e36-e51, 2011.

[50] I. M. Conboy, M. J. Conboy, A. J. Wagers, E. R. Girma, I. L. Weissman, and T. A. Rando, "Rejuvenation of aged progenitor cells by exposure to a young systemic environment," Nature, vol. 433, no. 7027, pp. 760-764, 2005.

[51] M. Sinha, Y. C. Jang, J. Oh et al., "Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle," Science, vol. 344, no. 6184, pp. 649-652, 2014.

[52] F. S. Loffredo, M. L. Steinhauser, S. M. Jay et al., "Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy," Cell, vol. 153, no. 4, pp. 828-839, 2013.

[53] J. L. Bueno, M. Ynigo, C. de Miguel et al., "Growth differentiation factor 11 (GDF11) - a promising anti-ageing factor - is highly concentrated in platelets," Vox Sanguinis, vol. 111, no. 4, pp. 434-436, 2016.

[54] M. Nakashima, K. Mizunuma, T. Murakami, and A. Akamine, "Induction of dental pulp stem cell differentiation into odontoblasts by electroporation-mediated gene delivery of growth/differentiation factor 11 (Gdf11)," Gene Therapy, vol. 9, no. 12, pp. 814-818, 2002.

[55] R. Liu-Bryan and R. Terkeltaub, "Emerging regulators of the inflammatory process in osteoarthritis," Nature Reviews Rheumatology, vol. 11, no. 1, pp. 35-44, 2015.

[56] M. Maumus, C. Manferdini, K. Toupet et al., "Adipose mesenchymal stem cells protect chondrocytes from degeneration associated with osteoarthritis," Stem Cell Research, vol. 11, no. 2, pp. 834-844, 2013.

[57] A. Mobasheri and Y. Henrotin, "Identification, validation and qualification of biomarkers for osteoarthritis in humans and companion animals: mission for the next decade," The Veterinary Journal, vol. 185, no. 2, pp. 95-97, 2010.

[58] J. M. Vilar, M. Morales, A. Santana et al., "Controlled, blinded force platform analysis of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells associated to PRGF-Endoret in osteoarthritic dogs," BMC Veterinary Research, vol. 9, p. 131, 2013.

[59] J. M. Vilar, M. Batista, M. Morales et al., "Assessment of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells in osteoarthritic dogs using a double blinded force platform analysis," BMC Veterinary Research, vol. 10, no. 1, p. 143, 2014.

Maravillas Mellado-Lopez, (1) Richard J. Griffeth, (1) Jose Meseguer-Ripolles, (1) Ramon Cugat, (2, 3) Montserrat Garcia, (2, 3) and Victoria Moreno-Manzano (1, 4)

(1) Tissue and Neuronal Regeneration Laboratory, Centro de Investigacion Principe Felipe, Valencia, Spain

(2) Unidad de Artroscopia y Unidad de Traumatologia del Hospital Quiron, Barcelona, Spain

(3) Fundacion Garcia Cugat, Barcelona, Spain

(4) FactorStem Ltd., Valencia, Spain

Correspondence should be addressed to Victoria Moreno-Manzano;

Received 30 May 2017; Revised 25 July 2017; Accepted 5 September 2017; Published 15 November 2017

Academic Editor: Xuekun Li

Caption: FIGURE 1: PRGF induces proliferation and migration of human ASCs. (a) Left: Human ASCs were cultured with HS or PRGF at growing concentration (1, 2.5, 5, or 10%) or in the absent of growth factors (0%) for 24 hours and subjected to cell viability test analysis. 10% PRGF induced a significant difference on the cell numbers in comparison with 10% of HS; * P > 0.05 versus 0% and $ P > 0.05 versus 10% HS; Right: representative phase-contrast images of ASCs 24 hours after incubation with 10% HS or 10% PRGF; scale bar: 100 [micro]m. (b) Cell migration and invasion assay was performed in 96-well plates by the IncuCyte S3 live-cell analysis. Left: cell density quantification at the wound area showed a faster and significant increase of cell density induced by 10% of PRGF since 2 hours after stimulation. 10% HS significantly induced the cell migration and invasion in comparison with 0% since 10 hours of incubation. *** P > 0.001; * P > 0.05. Right: representative phase-contrast images of human ASCs in the presence of different concentrations of HS or PRGF 16 hours after incubation.

Caption: FIGURE 2: PRGF prevents in vitro ASC aging. (a) Senescence cell quantification was performed by quantification of SA[beta]Gal-positive cells in bright field microscope at 20x magnification. Four different fields, containing a minimum of 200 cells, were analysed in three independent experiments. (b) Autophagosome quantification was performed from higher magnification TEM pictures from at least 200 different cells. The total number of autophagosomes was normalized to the total area analyzed with ImageJ software. Three independent experiments were analysed and represented as the mean [+ or -] SD of autophagosomes/total cell area ([px.sup.2]) ** P > 0 01; *** P > 0 0001.

Caption: FIGURE 3: PRGF accelerates adipocyte, osteocyte, and chondrocyte in vitro differentiation of human ASCs. Human ASCs were induced to differentiate toward the three mesodermal lineages in the presence or absence of 2.5% PRGF; (a) adipogenesis: the presence of PRGF induced higher intracellular lipid content by Oil Red O staining; (b) osteogenesis: both calcium deposits visualized by Alizarin Red staining and the phalloidin (green: which indicates actin cytoskeleton growth in osteocytes) and Cx43 expression (red: a known marker of mature osteocytes) were improved in the presence of PRGF; (c) chondrogenesis: Alcian blue staining (marker of the proteoglycan aggrecan deposits) and immunostaining of Sox9 (green: marker of chondrogenesis and chondrocyte differentiation) were higher in the presence of PRGF. Scale bar: 50 [micro]m. * P < 005 versus 0% PRGF.

Caption: FIGURE 4: AKT mediates PRGF survival and prevention of [H.sub.2][O.sub.2] cytotoxicity. (a) Human ASCs were treated with 100 [micro]M [H.sub.2][O.sub.2] for 24 h in the presence or absence (0%) of 2.5% PRGF or 2.5% HS, and the cell viability was analyzed by MTT assay. The significant reduction on cell viability induced by hydrogen peroxide was prevented by 2.5% of PRGF. * P < 0.05 versus 0 [micro]M [H.sub.2][O.sub.2] and # P < 0 05 versus 100 [micro]M [H.sub.2][O.sub.2]. (b) Preincubation with 10 [micro]M of the AKT inhibitor (Calbiochem, VIII 124018) abolished the cell protective effect of PRGF of the cytotoxic effects of 100 [micro]M [H.sub.2][O.sub.2]. *P < 0.05 versus 0% PRGF. (c) FACS analysis of annexin V showed the percentage of apoptotic cells according to each treatment. #P < 0.05 versus 2.5% PRGF. (d) Western blot analysis of total protein lysates of the human ASCs treated with 2.5% PRGF (+) or 0% PRGF (-) in the presence of 100 [micro]M, preincubated or not for 30 min with 10 [micro]M AKT inhibitor for 24 h. Activation or cleavage of the apoptotic protein PARP is confirmed when two bands visible. [beta]-Actin was employed as a loading control. Representative blots of three different experiments are shown; * P < 0.05.
COPYRIGHT 2017 COPYRIGHT 2010 SAGE-Hindawi Access to Research
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Mellado-Lopez, Maravillas; Griffeth, Richard J.; Meseguer-Ripolles, Jose; Cugat, Ramon; Garcia, Mont
Publication:Stem Cells International
Article Type:Report
Date:Jan 1, 2017
Previous Article:Isolation and Molecular Characterization of Amniotic Fluid-Derived Mesenchymal Stem Cells Obtained from Caesarean Sections.
Next Article:Mesenchymal Stem Cells for Cartilage Regeneration of TMJ Osteoarthritis.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters